



WHAT YOU SHOULD KNOW ABOUT **MOLNUPIRAVIR**

February 25, 2022

Michigan.gov/Coronavirus

On December 23, 2021, the FDA issued an EUA for molnupiravir (MERCK) for the treatment of mild to moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options are not accessible or clinically appropriate.

A qualified health care provider will determine whether you are a candidate for molnupiravir and if you are within the five-day window of symptom onset. It is important to remember that this medication is not a substitute for the COVID-19 vaccine.

How does molnupiravir work?

Molnupiravir keeps the virus that causes COVID-19 from reproducing, which helps rid the body of the virus and helps you get better.

Who can take molnupiravir?

A qualified health care provider may prescribe molnupiravir for patients with the following:

- Are over the age of 18
- Are able to start the medication within five days of the onset of symptoms.
- Someone who does not have timely access to alternative COVID-19 medications (like monoclonal antibody therapy).

Can I take molnupiravir if I'm pregnant or breast feeding?

Molnupiravir should not be used for anyone who is pregnant/and or breastfeeding.

How is molnupiravir given?

- 800 mg (four 200 mg capsules) taken by mouth every 12 hours for five days, with or without food.
- Completion of the full five-day treatment is recommended.
- Reported side effects include diarrhea, nausea and dizziness.

Further information for patients and caregivers: [Fact Sheet for Patients and Caregivers](#)
[Emergency Use Authorization \(EUA\) of Molnupiravir](#)